Cell>Point touts SPECT agent results at SNM

Jun 8, 2010

Radiopharmaceutical developer Cell>Point of Centennial, CO, highlighted clinical results for its cancer imaging agent at the SNM annual meeting in Salt Lake City.

The firm's technetium-99m-labeled glucosamine (Tc-99m ECG) is a SPECT cancer imaging agent that Cell>Point is developing as an alternative to FDG-PET for diagnosing and staging patients with cancer.

Cell>Point enrolled seven patients with non-small cell lung cancer who were receiving chemotherapy as part of a phase I trial performed to assess dosimetry, biodistribution, and pharmacokinetics of the agent. All patients were imaged with FDG-PET to assess the efficacy of chemotherapy. Investigators performed Tc-99m ECG SPECT imaging to compare with the PET findings.

Image interpretation showed a one-to-one correspondence between FDG-PET and Tc-99m ECG SPECT for all primary lesions. For PET, all primary lesions had a fluffy appearance and were larger than noted on the pretreatment PET, consistent with chemotherapy inflammatory response. For SPECT, the primary lesions were smaller and more discrete, with clinical findings of chemotherapy efficacy, Cell>Point said.

Biotech firm Cell>Point sees promise for oncology SPECT, May 20, 2005

Philips adds molecular imaging partnership, September 29, 2003

$ChatGPT powered by GPT-4 and using DALL-E−3 was asked to generate an image for teaching purposes that demonstrated: a nuclear medicine bone scan with skeletal metastases (top left); coronary artery disease (top right); an F-18 FDG-PET scan of the brain with Alzheimer's disease (bottom left); and an x-ray showing a fracture (bottom right). These are misleading for educational purposes and for patients who may be searching for information. Image and caption courtesy of Radiography.$